P3‐261: Concurrent validity of the Alzheimer's Questionnaire (AQ)

Malek‐Ahmadi, Michael; Davis, Kathryn; Belden, Christine M.; Sabbagh, Marwan

doi:10.1016/j.jalz.2012.05.1484

Cited by 2 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Computerized neuropsychological assessment batteries were performed using CNS Vital Signs, which samples multiple domains (verbal memory, visual memory, simple attention, complex attention, cognitive flexibility, executive function, processing speed, psychomotor speed, motor speed, and reaction time) as well as providing an overall Neurocognitive Index (NCI) and composite memory score. The AQ-21 (Alzheimer's Questionnaire) is an informant-based subjective assessment with sensitivity and specificity for amnestic MCI and AD of over 90%,16 answered by the significant other or study partner, with scores ranging from 0 (no problems noted) to 27 (all positive responses to questions regarding impairment). A score of 5-14 suggests mild cognitive impairment, and 15-27 suggests dementia.…”

mentioning

confidence: 99%

Precision Medicine Approach to Alzheimer’s Disease: Successful Proof-of-Concept Trial

Toups¹,

Hathaway

Gordon

et al. 2021

Preprint

View full text Add to dashboard Cite

Importance: Effective therapeutics for Alzheimer's disease and mild cognitive impairment are needed. Objective: To determine whether a precision medicine approach to Alzheimer's disease and mild cognitive impairment, in which potential contributors to cognitive decline are identified and targeted therapeutically, is effective enough in a proof-of-concept trial to warrant a larger, randomized, controlled clinical trial. Rationale: Previous clinical trials for Alzheimer's disease have pre-determined a single treatment modality, such as a drug candidate or therapeutic procedure, that may be unrelated to the primary drivers of the neurodegenerative process. Therefore, increasing data set size to include the potential contributors to cognitive decline for each patient, and addressing the identified potential contributors, may represent a more effective therapeutic strategy. Hypothesis: Alzheimer's disease is a multi-factorial network dysfunction that results from a chronic or repeated insufficiency of support for a neuroplasticity network; thus factors that increase demand — such as infections or toxin exposure — or reduce support — such as reduced energetics or trophic support — may contribute to the neurodegenerative process. Rectifying this hypothesized network dysfunction represents a rational approach to the treatment of the cognitive decline associated with Alzheimer's disease and mild cognitive impairment. Design: Twenty-five patients with Alzheimer's disease or mild cognitive impairment, with Montreal Cognitive Assessment (MoCA) scores of 19 or higher, were evaluated for markers of inflammation, chronic infection, dysbiosis, insulin resistance, protein glycation, vascular disease, nocturnal hypoxemia, hormone insufficiency or dysregulation, nutrient deficiency, toxin or toxicant exposure (metals, organic toxicants, and biotoxins), genetic predisposition to cognitive decline, and other biochemical parameters associated with cognitive decline. Brain magnetic resonance imaging with volumetrics was performed at baseline and study conclusion. Patients were treated for nine months with a personalized, precision medicine protocol that addressed each patient's identified potentially contributory factors, and cognition was assessed at t = 0, 3, 6, and 9 months. Trial registration and IRB approval: The clinical trial was registered at clinicaltrials.gov (NCT03883633), 1 and approved by the Advarra IRB. Support for the trial: The trial was supported by a grant from the Four Winds Foundation via Evanthea, LLC, and we are grateful to Diana Merriam and Gayle Brown for their interest, discussions, and support. Main Outcome Measures: Trained external raters evaluated the study subjects with the Montreal Cognitive Assessment (MoCA), CNS Vital Signs (a computerized cognitive assessment battery), AQ-21 (a subjective scale completed by the significant other or study partner), and AQ-C change scale (a subjective scale of cognitive improvement or decline, completed by the significant other or study partner). Follow-up brain MRI with volumetrics was carried out at the completion of the trial. Results: All outcome measures revealed improvement: statistically highly significant improvement in MoCA scores, CNS Vital Signs Neurocognitive Index, and AQ-C were documented. No serious adverse events were recorded. Conclusions and Relevance: Based on the cognitive improvements observed in this study of patients with Alzheimer's disease or mild cognitive impairment, a larger, randomized, controlled trial of the precision medicine therapeutic approach described herein is warranted.

show abstract

mentioning

confidence: 99%

Precision Medicine Approach to Alzheimer’s Disease: Successful Proof-of-Concept Trial

Toups¹,

Hathaway

Gordon

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The test, according to American scientists, correlates with neuropsychological tests, is "a reliable indicator of cognitive impairment and accurately identifies Alzheimer's disease (AD) and moderate cognitive impairment (MCI), is easily interpreted and helps to identify cognitive impairment at an early stage in 90% of cases" [5,6]. It is known about the conduct and publication of a number of studies confirming the diagnostic accuracy and psychometric reliability of the Arizona Questionnaire [7]. The superiority of AQ over objective cognitive tests and comparability with other questionnaires based on informants and patients are also shown [8,9].…”

Section: Introductionmentioning

confidence: 99%

Informant-based questionnaire for early detection of cognitive disorders in the olders in Kazakhstan

2022

View full text Add to dashboard Cite

The purpose of this study was to identify cognitive disorders in older people by conducting a survey of their relatives (close people) by the Arizona Questionnaire.Material and methods: The study involved people who had relatives (close ones) aged 60-74 years old. Three hundred and eighty respondents took part in the survey.Results: Summing up all the points obtained during the survey of relatives 4-13 points 78.7% (n=299), which may indicate the presence of moderate cognitive disorders that are better not to be ignored (suggests going to the doctor) and above 13 points 6% (n=23) indicates a fairly high probability of dementia (urgent need to seek medical help). Our study revealed that family status (p<0.001), employment (p=0.014), and recitation of namaz (p=0.009) act as protective factors that promote social participation and build cognitive reserve. Social isolation, on the other hand, can lead to apathy, withdrawal, depression, and a greater likelihood of cognitive impairment. We also found that place of residence (p<0.001) and living conditions (p=0.002), may also influence the early formation of cognitive dysfunctions. Arizona Questionnaire has high sensitivity and specificity in detecting both mild cognitive impairments and Alzheimer's disease and allows clinicians to quickly and accurately assess people with reported cognitive problems. Conclusion:As a result of survey informants, it was revealed that most of the olders, whose relatives have been surveyed, may be at risk of cognitive impairment and further testing is needed.

show abstract

P3‐261: Concurrent validity of the Alzheimer's Questionnaire (AQ)

Cited by 2 publications

References 13 publications

Precision Medicine Approach to Alzheimer’s Disease: Successful Proof-of-Concept Trial

Precision Medicine Approach to Alzheimer’s Disease: Successful Proof-of-Concept Trial

Informant-based questionnaire for early detection of cognitive disorders in the olders in Kazakhstan

Contact Info

Product

Resources

About